- Vaccinated people generated an overall protective immune response to the Delta and Omicron strains of COVID-19, though with slightly fewer antibodies for the mutated parts of the virus.
- University of Arizona Health Sciences researchers found that people who received the original COVID-19 vaccine had greater antibody production against the Delta and Omicron variants than those who were unvaccinated.
- Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the Delta and Omicron strains, though new mutation-specific antibody production dipped slightly, according to a study led by researchers at the University of Arizona Health Sciences and published in Nature Immunology.
Author Archive: AZBio
Study reveals weakness in rare ovarian cancer tumors that may lead to improved treatment options
Findings could suggest new targets for immunotherapy
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Cargill’s Bioindustrial business Partners with Arizona State University to Explore New Materials for Semiconductor Innovation
TEMPE, Ariz. (May 15, 2025) — Cargill Bioindustrial and Arizona State University (ASU) are launching a new, year-long research partnership focused on advanced materials used in semiconductor technology — the foundation of modern electronics from smartphones to electric vehicles.
The research is focused on Cargill™ Priamine™ dimer diamine, which is made from bio-based ingredients. With support from ASU’s Biodesign Institute, scientists will study how and why this material performs so well, and how it might be used to improve the speed, efficiency, and reliability of electronic devices.Continue reading
Navigating CRO and CMO Relationships – AZBioPEERS Video
Selecting and managing the right CRO or CMO partner can make or break an early-stage company’s path to market. Join us for a practical, insight-packed webinar exploring how to evaluate, engage, and grow with outsourcing partners that align with your technical needs, regulatory goals, and growth plans.Continue reading
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
- The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment.
- The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods.
- This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology.
Genetic Factors May Influence Liver Fat Even in Healthy Weight People
TGen Study improves our understanding of steatotic liver disease in an understudied population
The Sun Devil who revolutionized kitty litter
A pioneering chemist and educator, Barbara Munk left an indelible mark on household products and science education. Continue reading
Health Innovation Leaders Respond to the Executive Order on Most Favored Nations Pricing
On May 12, 2025, President Donald J. Trump signed Executive Order DELIVERING MOST-FAVORED-NATION PRESCRIPTION DRUG
PRICING TO AMERICAN PATIENTS that establishes a requirement for Most Favored Nations Prescription Drug Pricing.
Section 5 of the EO states: “Within 30 days of the date of this order, the Secretary shall, in coordination with the Assistant to the President for Domestic Policy, the Administrator for the Centers for Medicare and Medicaid Services, and other relevant executive department and agency (agency) officials, communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.”
The intent is to obtain the lowest prices offered by drug companies in other wealthy countries, known as “most-favored-nation” (MFN) pricing, and to take action if those prices aren’t extended to Americans. It also calls for direct-to-consumer programs, drug importation from countries with lower costs, and antitrust enforcement against companies that block price competition.Continue reading
Responses to The Administration’s Section 232 Inquiry into Pharmaceutical Imports
“The Trump administration’s Section 232 inquiry into pharmaceutical imports represents a pivotal moment for the sector. Leaders in pharmaceutical supply chains must adjust and create solutions to maintain access to essential medications while responding to the changing trade environment.” — Srihari Rangarajan, EY Americas Life Sciences Supply Chain LeaderContinue reading